Log in

Xeris Pharmaceuticals Stock Price, News & Analysis (NASDAQ:XERS)

$9.01
+0.01 (+0.11 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$8.92
Now: $9.01
$9.39
50-Day Range
$7.61
MA: $9.76
$11.59
52-Week Range
$6.85
Now: $9.01
$25.49
Volume157,362 shs
Average Volume121,206 shs
Market Capitalization$243.18 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.44
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XERS
CUSIPN/A
CIKN/A
Phone844-445-5704

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.46 million
Book Value$3.61 per share

Profitability

Net Income$-60,080,000.00
Net Margins-4,876.50%

Miscellaneous

Employees90
Market Cap$243.18 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive XERS News and Ratings via Email

Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.


Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals Inc (NASDAQ:XERS) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($1.28) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.94) by $0.34. The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.20 million. Xeris Pharmaceuticals had a negative net margin of 4,876.50% and a negative return on equity of 107.65%. View Xeris Pharmaceuticals' Earnings History.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Xeris Pharmaceuticals.

What price target have analysts set for XERS?

2 analysts have issued 1-year price objectives for Xeris Pharmaceuticals' shares. Their predictions range from $18.00 to $27.00. On average, they expect Xeris Pharmaceuticals' stock price to reach $22.50 in the next year. This suggests a possible upside of 149.7% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

What is the consensus analysts' recommendation for Xeris Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

What are Wall Street analysts saying about Xeris Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
  • 1. Mizuho analysts commented, "We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%)." (9/10/2019)
  • 2. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019)

Has Xeris Pharmaceuticals been receiving favorable news coverage?

News stories about XERS stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Xeris Pharmaceuticals.

Are investors shorting Xeris Pharmaceuticals?

Xeris Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 2,450,000 shares, an increase of 17.2% from the August 15th total of 2,090,000 shares. Based on an average daily trading volume, of 196,700 shares, the short-interest ratio is presently 12.5 days. Currently, 11.0% of the company's shares are sold short. View Xeris Pharmaceuticals' Current Options Chain.

Who are some of Xeris Pharmaceuticals' key competitors?

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include TG Therapeutics (TGTX), Pareteum (TEUM), Omeros (OMER), Ovid Therapeutics (OVID), Pieris Pharmaceuticals (PIRS), GAP (GPS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA) and Arrowhead Pharmaceuticals (ARWR).

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
  • Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
  • Mr. John P. Shannon, Exec. VP & COO (Age 57)
  • Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $9.01.

How big of a company is Xeris Pharmaceuticals?

Xeris Pharmaceuticals has a market capitalization of $243.18 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.

What is Xeris Pharmaceuticals' official website?

The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/.

How can I contact Xeris Pharmaceuticals?

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]


MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel